Skip to content
Back to PLRX

Pliant Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
4
Purchases
0
Sales
4
Purchase value
$0.00
Sale value
$163.62K

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Keith Lamont CummingsChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jan 22, 2026Period of report Jan 20, 20260001746473-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 20, 2026
Common StockF1F224,002$1.28$30.72K297,214Direct
Filing footnotes · 2
  1. F1Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.
  2. F2Includes 1,958 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.
Open on SEC EDGAR
Lily CheungChief Human Resource Officer
4Rule 10b5-1 plan disclosed
Filed Jan 22, 2026Period of report Jan 20, 20260001746473-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 20, 2026
Common StockF1F27,534$1.28$9.64K44,847Direct
Filing footnotes · 2
  1. F1Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.
  2. F2Includes 1,956 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.
Open on SEC EDGAR
Bernard CoulieDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Jan 22, 2026Period of report Jan 20, 20260001746473-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 20, 2026
Common StockF1F289,375$1.28$114.40K505,601Direct
Filing footnotes · 3
  1. F1Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.
  2. F2Includes 1,959 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase program.
  3. F3Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
Minnie KuoChief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Jan 22, 2026Period of report Jan 20, 20260001746473-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 20, 2026
Common StockF16,917$1.28$8.85K37,806Direct
Filing footnotes · 1
  1. F1Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.